Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake.

Journal Information

Full Title: Int J Obes (Lond)

Abbreviation: Int J Obes (Lond)

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Metabolism

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests CM has received support from Novo Nordisk A/S for organizing/attending meetings. JEBJ and SST have received research grants and lecture fees from Novo Nordisk A/S. CD has served as advisor for Novo Nordisk A/S and AstraZeneca and received lecture fees from Novo Nordisk A/S. NBJ has served on advisory panels and in educational programs from Novo Nordisk A/S, has received research support from Boehringer Ingelheim Denmark. In addition, NBJ reports having taken a position with Novo Nordisk A/S as of March 2023. The remaining authors have no competing interests related to this study."

Evidence found in paper:

"Funding Open access funding provided by Royal Library, Copenhagen University Library."

Evidence found in paper:

"Eligible patients were identified using a database of > 600 patients operated with RYGB at Copenhagen University Hospital Hvidovre, Denmark in 2012–2015. Patients with primary WL failure (LowEBMIL, n = 20) were defined by postoperative EBMIL < 50% at all visits including 1 and 2 years postoperatively after uncomplicated RYGB. Each patient in the primary WL failure group was matched individually with one patient with successful WL (postoperative EBMIL > 60%, HighEBMIL, n = 20) with respect to age, preoperative BMI and time from RYGB. Only women without a history of diabetes (Hba1c < 48 mmol/mol without glucose-lowering medication) were included. Exclusion criteria were unstable weight (self-reported > ±3 kg in 3 months), inadequately treated hypothyroidism, use of antithyroid medication or medication affecting appetite, hemoglobin < 6.5 mmol/L, pregnancy/breastfeeding or unwillingness/allergies toward the test meals. The study was approved by the Regional Ethical Committee of the Capital Region (H-4–2014–007), by the Danish Data Protection Agency and was performed in accordance with the Helsinki declaration and registered at ClinicalTrials.gov (NCT02344632). Written informed consent was obtained from all participants before inclusion."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025